卡德萊蒂斯公司
US ˙ NasdaqGM ˙ US14161W1053

SecurityCDLX / Cardlytics, Inc.
InstitutionBrooktree Capital Management
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Brooktree Capital Management closes position in CDLX / Cardlytics, Inc.

On November 7, 2025 - Brooktree Capital Management filed a 13F-HR form disclosing ownership of 0 shares of Cardlytics, Inc. (US:CDLX) valued at $0 USD as of September 30, 2025. The entity filed a previous 13F-HR on August 6, 2025 disclosing 242,249 shares of Cardlytics, Inc.. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-11-07 2025-09-30 13F CARDLYTICS COM 14161W105 0 -100.00 0
2025-08-06 2025-06-30 13F CARDLYTICS COM 14161W105 242,249 18,624 8.33 398 -1.97 0.2606
2025-05-06 2025-03-31 13F CARDLYTICS COM 14161W105 223,625 48,415 27.63 407 -37.54 0.3054
2025-02-10 2024-12-31 13F CARDLYTICS COM 14161W105 175,210 7,568 4.51 650 21.27 0.4820
2024-11-06 2024-09-30 13F CARDLYTICS COM 14161W105 167,642 33,169 24.67 536 -51.45 0.4357
2024-08-05 2024-06-30 13F CARDLYTICS COM 14161W105 134,473 -4,497 -3.24 1,104 -45.16 0.9441
2024-05-06 2024-03-31 13F CARDLYTICS COM 14161W105 138,970 21,150 17.95 2,014 85.53 1.5530
2024-02-05 2023-12-31 13F CARDLYTICS COM 14161W105 117,820 -1,422 -1.19 1,085 -44.84 0.8770
2023-11-06 2023-09-30 13F CARDLYTICS COM 14161W105 119,242 -1,216 -1.01 1,967 158.48 1.6433
2023-08-08 2023-06-30 13F CARDLYTICS COM 14161W105 120,458 3,594 3.08 761 92.17 0.5788
2023-05-08 2023-03-31 13F CARDLYTICS COM 14161W105 116,864 75,596 183.18 397 66.39 0.3089
2023-02-07 2022-12-31 13F CARDLYTICS COM 14161W105 41,268 -55,252 -57.24 239 -73.76 0.1960
2022-11-07 2022-09-30 13F CARDLYTICS COM 14161W105 96,520 62,486 183.60 907 19.50 0.7468
2022-08-08 2022-06-30 13F CARDLYTICS COM 14161W105 34,034 15,393 82.58 759 -25.95 0.5702
2022-05-09 2022-03-31 13F CARDLYTICS COM 14161W105 18,641 18,641 1,025 0.6681
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.